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A B S T R A C T
Ferroptosis has been deﬁned as an oxidative and iron-dependent pathway of regulated cell death that is distinct
from caspase-dependent apoptosis and established pathways of death receptor-mediated regulated necrosis.
While emerging evidence linked features of ferroptosis induced e.g. by erastin-mediated inhibition of the Xc
-
system or inhibition of glutathione peroxidase 4 (Gpx4) to an increasing number of oxidative cell death
paradigms in cancer cells, neurons or kidney cells, the biochemical pathways of oxidative cell death remained
largely unclear. In particular, the role of mitochondrial damage in paradigms of ferroptosis needs further
investigation.
In the present study, we ﬁnd that erastin-induced ferroptosis in neuronal cells was accompanied by BID
transactivation to mitochondria, loss of mitochondrial membrane potential, enhanced mitochondrial fragmen-
tation and reduced ATP levels. These hallmarks of mitochondrial demise are also established features of
oxytosis, a paradigm of cell death induced by Xc
- inhibition by millimolar concentrations of glutamate. Bid
knockout using CRISPR/Cas9 approaches preserved mitochondrial integrity and function, and mediated
neuroprotective eﬀects against both, ferroptosis and oxytosis. Furthermore, the BID-inhibitor BI-6c9 inhibited
erastin-induced ferroptosis, and, in turn, the ferroptosis inhibitors ferrostatin-1 and liproxstatin-1 prevented
mitochondrial dysfunction and cell death in the paradigm of oxytosis. These ﬁndings show that mitochondrial
transactivation of BID links ferroptosis to mitochondrial damage as the ﬁnal execution step in this paradigm of
oxidative cell death.
1. Introduction
Oxidative stress is a well-accepted paradigm mediating neuronal
dysfunction and death in age-related neurodegenerative diseases such
as Alzheimer's disease (AD) and Parkinson's disease (PD). In according
experimental settings investigating the underlying mechanisms in the
diﬀerent paradigms of neurodegeneration, deregulated intracellular
calcium homeostasis and oxidative stress were identiﬁed as common
triggers of death signaling in neurons. Such pathways of programmed
cell death (PCD) converge at the mitochondria, the key organelles of
energy metabolism which secure neuronal functions and survival under
physiological conditions [18]. In paradigms of programmed cell death,
mitochondrial dysfunction is associated with mitochondrial fragmenta-
tion, permeabilization of the outer mitochondrial membrane (MOMP)
and the release of pro-apoptotic proteins such as cytochrome c or
apoptosis-inducing factor (AIF) from the intermembrane space into the
cytosol, where they orchestrate the ﬁnal steps of PCD [18,4]. The
molecular pathways mediating mitochondrial damage and neuronal
death in response to oxidative stress, however, are still poorly deﬁned.
Understanding how these highly regulated neuronal cell death pro-
grams are activated and lead to neuronal demise is of great scientiﬁc
and clinical relevance.
Oxytosis is one paradigm of oxidative cell death that has been
established in neuronal cells [16,24]. Lethal signaling pathways related
to oxytosis can be induced in neuronal cells by glutamate-mediated
inhibition of the cystine-glutamate antiporter (Xc
-) thereby depleting
the intracellular pool of glutathione (GSH) [23]. Reduced GSH levels
impair the redox defense of neuronal cells, thus increasing intracellular
ROS levels that trigger caspase-independent cell death [16,24]. In
particular, GSH depletion reduces the activity of glutathione perox-
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idase-4 (Gpx4) and increases 12/15-lipoxygenase (LOX) activity, which
are key events upstream of mitochondrial dysfunction [21,25,26]. In
paradigms of oxytosis in neuronal cells, mitochondrial impairments are
mediated through mitochondrial transactivation of the pro-apoptotic
protein BID [13,16,25]. Upon translocation to the mitochondria, BID
mediates loss of mitochondrial integrity and function and detrimental
translocation of mitochondrial AIF to the nucleus [12,13,19,21,24–
26,5].
The concept of ferroptosis has recently been introduced as an iron-
dependent form of oxidative cell death in cancer cells and in neurons
[7]. Later, features of ferroptotic cell death have also been observed in
kidney cells [17,9]. The paradigm of ferroptosis involves the generation
of soluble and lipid ROS through iron-dependent enzymatic reactions
which are, for example, mediated by lipoxygenases, xanthine oxidases,
NADPH oxidase or catalase [27,8]. In addition to iron-chelating
compounds, ferroptosis can be blocked by ferrostatin-1, a potent
inhibitor which mediates protective eﬀects against erastin-induced
ferroptosis by inhibiting lipid peroxidation [27,7]. Further, mechan-
isms of ferroptosis have been identiﬁed in neurons, in death signaling
pathways induced by cerebral ischemia [22] and in glutamate-induced
neurotoxicity in organotypic hippocampal slice cultures [7]. Similarly
as in glutamate-induced oxytosis, erastin activates ferroptosis by
inhibiting the Xc
- transporter. In contrast to the paradigms of oxytosis,
however, ferroptosis in cancer cells did not involve mitochondrial
damage [7]. In ﬁbroblasts and kidney cells, ferroptosis was accom-
panied by alterations in mitochondrial morphology and integrity,
including reduced organelle size and vanishing of mitochondrial
cristae, condensed mitochondrial membrane densities and rupture of
the mitochondrial outer membrane, respectively [27].
The biochemical mechanisms linking oxidative stress to mitochon-
drial damage in ferroptosis, however, has not yet been clariﬁed.
Further, how the emerging concepts of oxytosis and ferroptosis may
converge, particularly in intrinsic death signaling involving mitochon-
drial dysfunction is largely unclear. In the present study, we found that
pathways of ferroptosis and oxytosis are linked via BID and subsequent
mitochondrial damage.
2. Materials and methods
2.1. Cell culture
HT-22 cells were grown in Dulbecco's modiﬁed Eagle medium
(DMEM, Capricorn) with the addition of 10% heat-inactivated fetal calf
serum, 100 U/ml penicillin, 100 mg/ml streptomycin and 2 mM glu-
tamine. For inducing cell death, diﬀerent concentrations of glutamate
(2–8 mM) or erastin (0.25–1 µM) were added to the medium for the
indicated amount of time.
Ferrostatin-1 and BI-6c9 were dissolved in DMSO and used in a
concentration of 2 µM and 10 µM, respectively.
MEF cells (mouse embryonic ﬁbroblasts) were cultured in DMEM
which was supplemented with 10% heat-inactivated fetal calf serum,
100 U/ml penicillin, 100 µg/ml streptomycin and 2 mM glutamine.
2.2. Generation and sequencing of HT-22 Bid KO cells
Wild-type (WT) HT-22 cells were seeded in 6-well plates at a
density of 100,000 cells/well and after 24 h, transfected with 5 µg Bid
CRISPR plasmid (U6gRNA-Cas9-2A-GFP; MM0000220718, Sigma
Aldrich, Taufkirchen) using 4.5 µl Attractene (Qiagen) and up to
250 µl OptiMEM/well. Two days later, transfection eﬃciency was
conﬁrmed by ﬂuorescence microscopy and cells were harvested with
trypsin. Afterwards, cells were sorted via FACS and single cells were
seeded into a 96-well plate. In order to exclude dead cells, cells were co-
stained with DAPI. Cells were cultured with weekly media change to
obtain appropriate amount of cells for further analysis.
For sequencing, genomic DNA was puriﬁed with the Invitrap® Spin
Universal RNA Mini Kit followed by the ampliﬁcation of a ~1000 bp
sequence (CRISPR region) using the following primers (5′ −3′):
AGCCCTGAACGGAAACATGG, CAGGCGGATCTCTGAGTTCG. Thereafter,
the ~1000 bp PCR product was puriﬁed by gel electrophoresis and DNA gel
extraction using the Promega Wizard® SV Gel and PCR Clean-Up System
according to the manufacturer's protocol and was sequenced accordingly.
2.3. Protein analysis and western blot
For protein analysis, cells were washed once with PBS and lysed
with buﬀer containing 0.25 M Mannitol, 0.05 M Tris, 1 M EDTA, 1 M
EGTA, 1 mM DTT, 1% Triton-X, supplemented with Complete Mini
Protease Inhibitor Cocktail and PhosSTOP (both Roche Diagnostics,
Penzberg, Germany). Extracts were centrifuged at 10,000×g for 15 min
at 4 °C to eliminate insoluble fragments. The total amount of protein
was determined by Pierce BCA Protein Assay Kit (Perbio Science,
Bonn, Germany). For Western Blot analysis, 50 µg of protein were
loaded on a 12.5% SDS-Gel and blotted onto a PVDF-membrane at
20 mA for 21 h. Incubation with primary antibody was performed
overnight at 4 °C. The following primary antibodies were used: BID
(Cell Signaling, Danvers, Massachusetts, USA) and Actin C4 (MB
Biomedicals, Illkirch Cedex, France). After incubation with a proper
secondary HRP-labeled antibody (Vector Laboratories, Burlingame,
CA, USA) Western Blot signals were detected by chemiluminescence
with Chemidoc software (Bio-Rad, Munich, Germany).
2.4. Plasmid transfection
For ﬂuorescence-activated cell sorting (FACS) analysis, 35,000
cells/well were seeded in 24-well plates and allowed to grow overnight.
The next day cells were pre-treated for 1 h with 10 µM BI-6c9 (Sigma
Aldrich) or 2 µM ferrostatin-1 (Sigma Aldrich), respectively and
plasmid transfection was performed. A transfection mix consisting of
2 µg tBID plasmid or pcDNA 3.1 dissolved in OptiMEM I and
Attractene (4.5 µl/well) was prepared. The tBid vector was generated
as described previously [16]. After 20 min of incubation at room
temperature cells were transfected with the mix. The plasmid pcDNA
3.1 (Invitrogen, Karlsruhe, Germany) was used as a control vector. Cell
death was analyzed after the indicated amount of time by Annexin V/PI
staining (Promokine, Heidelberg, Germany).
For real time impedance measurements, 8000 cells/well were
seeded in 96-well Eplates and allowed to grow overnight. The next
day a transfection mix consisting of 0.75 µg pIRES tBID plasmid or
pcDNA 3.1 dissolved in OptiMEM I and Attractene (0.75 µl/well) was
prepared. After 20 min of incubation at room temperature cells were
transfected with the mix.
2.5. Cell viability
Cell viability was detected using the MTT assay. At indicated time
points of treatment 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazo-
lium bromide (MTT) was added at a concentration of 2.5 mg/ml for 1 h
at 37 °C to the culture medium. Afterwards, the purple formazan was
dissolved in DMSO and absorbance was measured at 570 nm versus
630 nm with FluoStar. The eﬀects of erastin and glutamate as well as
overexpression of tBID on cell viability in HT-22 Bid KO cells were
studied by real-time measurements of cellular impedance using the
xCELLigence system as previously described [6].
Additionally, cell viability of glutamate- and erastin-treated HT-22 and
HT-22 Bid KO cells as well as after tBID-overexpression was detected by an
Annexin V/PI staining using an Annexin-V-FITC Detection Kit followed by
FACS analysis. Annexin-V-FITC was excited at 488 nm and emission was
detected through a 530±40 nm band pass ﬁlter (Green ﬂuorescence).
Propidium iodide was excited at 488 nm and ﬂuorescence emission was
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detected using a 680±30 nm band pass ﬁlter (Red ﬂuorescence). Data
were collected from 10,000 cells from at least four wells per condition.
2.6. Glutathione measurement
To determine GSH levels, HT-22 WT and Bid KO cells were seeded
in 6-well plates (180,000 cells/well). After treatment with either
glutamate or erastin for the indicated amount of time two to three
wells per condition were harvested by scratching and washed once with
PBS. GSH measurements were performed using the Glutathione Assay
Kit (Cayman Chemical Company, Ann Arbor, USA) following manufac-
turer's protocol. Brieﬂy, cells were re-suspended in MES-buﬀer (0.4 M
2-(N-mopholino)ethanesulphonic acid, 0.1 M phosphate, 2 mM EDTA,
pH 6.0) and homogenized by soniﬁcation. Insoluble fragments were
removed by centrifugation at 10,000×g for 15 min. The supernatant
was deproteinated by the addition of an equal volume of metapho-
sphoric acid (1.25 M). After incubation for 5 min the mixture was
centrifuged at 17,000×g for 10 min. Subsequently, the supernatant was
mixed with a 4 M solution of triethanolamine to increase the pH. After
transferal into a 96-well plate, the assay cocktail containing provided
MES-buﬀer, co-factor mixture, enzyme mixture and Ellman's reagent
was added. Absorbance was measured at 405 nm after 30 min of
incubation. Total GSH amount was determined via standard curve
calculation and normalized to protein content.
2.7. Lipid peroxidation
For detection of lipid peroxidation, HT-22 cells were seeded in 24-
well plates with 55,000 cells/well. After treatment with erastin or
glutamate cells were stained with BODIPY 581/591 C11 (Invitrogen,
Karlsruhe, Germany) for 1 h at 37 °C in culture medium. For evalua-
tion of the inhibitors, cells were co-treated with BI-6c9 and erastin or
ferrostatin-1 and glutamate for the indicated amount of time before
staining with BODIPY 581/591 C11. After collecting and washing once
with PBS, cells were re-suspended in an appropriate amount of PBS.
Lipid peroxidation was analyzed by the detection of a ﬂuorescence shift
from green to red via FACS analysis. Excitation was performed at
488 nm and emission was recorded at 530 nm (green) and 585 nm
(red). Data were collected from at least 10,000 cells.
2.8. Mitochondrial ROS formation
Formation of mitochondrial reactive oxygen species (ROS) was
investigated via MitoSOX red staining (Invitrogen, Karlsruhe,
Germany). For detection of mitochondrial ROS production, HT-22 cells
were seeded in 24-well plates with 55,000 cells/well. After treatment with
erastin or glutamate, respectively, cells were stained with MitoSOX red for
30 min at 37 °C. After collecting and washing once with PBS, cells were
re-suspended in PBS and red ﬂuorescence was detected by FACS analysis.
Data were collected from at least 10,000 cells.
2.9. Mitochondrial morphology
For detection of changes in mitochondrial morphology cells were
stained with MitoTracker DeepRed (200 nM) for 20 min at 37 °C. In 8-
well ibidi slides 17,000 cells/well were seeded and staining was
performed before glutamate or erastin exposure. After the indicated
time of treatment, cells were ﬁxed with 4% paraformaldehyde for
20 min at RT. Mitochondria were divided into three categories as
previously described [13]. Brieﬂy, cells exhibiting elongated mitochon-
dria organized in a tubular network represented category I. Cells
predominantly showing large dotted mitochondria equally distributed
all over the cytosol were assigned to category II, whereas cells with
totally fragmented mitochondria surrounding the nucleus belong to
category III. At least 500 cells per condition were counted without
knowledge of treatment conditions. Images were acquired using a
ﬂuorescence microscope (63x objective). MitoTracker DeepRed ﬂuor-
escence was excited at a wavelength of 620 nm band pass ﬁlter and
emissions were detected using 670 nm long pass ﬁlter (red).
2.10. ATP measurement
For analysis of total ATP levels, cells were seeded in white 96-well
plates (8000 cells/well). At the indicated time points after glutamate or
erastin treatment, ATP levels were analyzed by luminescence detection
with FluoStar according to the manufacturer's protocol using the
ViaLight™plus Kit (Lonza, Verviers, Belgium).
2.11. Measurement of cellular oxygen consumption rate
To determine the cellular oxygen consumption rate, cells were plated
in XF96-well microplates (8000 cells/well, Seahorse Bioscience) and
treated with either erastin or glutamate. At indicated time points after
treatment OCR measurements were performed as previously described
[11] with minor modiﬁcations. Brieﬂy, the growth medium was washed
oﬀ and replaced by ~180 µl of assay medium (with 4.5 g/l glucose as the
sugar source, 2 mM glutamine, 1 mM pyruvate, pH 7.35) and cells were
incubated at 37 °C for 60 min. Three baseline measurements were
recorded before adding the compounds. Oligomycin was injected in port
A (20 µl) at a ﬁnal concentration of 3 µM, FCCP (22.5 µl in port B) at a
concentration of 0.5 µM and rotenone/antimycin A (25 µl in port C) at a
concentration of 100 nM and 1 µM, respectively. Three measurements
were performed after the addition of each compound (4 min mixing
followed by 3 min detection).
2.12. Mitochondrial membrane potential
In order to determine changes in the MMP in HT-22 cells after
glutamate and erastin exposure, the MitoPT TMRE Kit
(Immunochemistry Technologies, Hamburg, Germany) was used. For
detection of changes in MMP, HT-22 cells were seeded in 24-well
plates with 55,000 cells/well. After treatment with BI-6c9 and erastin
or ferrostatin-1 and glutamate, cells were collected and stained with
TMRE at a ﬁnal concentration of 200 nM for 20 min at 37 °C. After
washing with PBS cells were re-suspended in an appropriate amount of
assay buﬀer and TMRE ﬂuorescence was assessed by FACS analysis.
Data were collected from at least 10,000 cells.
2.13. BID translocation and confocal microscopy
For investigation of BID translocation cells were seeded in 8-well
ibidi slides at a density of 17,000 cells/well and transfected with the
pDSRed2-Bid vector (Clontech, Palo Alto, USA). To visualize the
mitochondria, cells were co-transfected with a mitochondrial-targeted
green ﬂuorescent protein (GFP). Transfection was achieved by using
Attractene transfection reagent according to the manufacturer's proto-
col. Twenty-four hours after transfection, cells were treated with either
erastin or glutamate. After the indicated time of treatment, cells were
ﬁxed with 4% paraformaldehyde. Images were acquired using a
confocal laser scanning microscope and light was collected through a
63×1.4 NA oil immersion objective. Mitochondrial GFP ﬂuorescence
was excited at 488 nm and emissions were detected between a
bandwidth of 500 nm and 535 nm. DSred2-BID ﬂuorescence was
detected by excitation at 633 nm and emission between 640 nm and
750 nm. For digital imaging, the software LSM Image Browser 4.2.0
(Carl Zeiss, Jena, Germany) was used. Quantiﬁcation of the LSM
images to show mitochondrial translocation of BID was performed
using the software ImageJ 1.48 v (Wayne Rasband, National Institutes
of Health, USA). The ﬂuorescence intensity along a deﬁned line in both
mito-GFP and DSRed2-BID images was determined by creating a plot
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proﬁle and values were used for further analysis of correlation.
Therefore, Pearson's coeﬃcient was calculated by Microsoft Excel
and given as mean ± standard deviation.
2.14. Statistical analysis
All data are presented as mean + standard deviation (SD).
Statistical comparison between treatment groups was performed by
analysis of variance (ANOVA) followed by Scheﬀé’s post hoc test.
Calculations were executed with Winstat standard statistical software
(R. Fitch Software, Bad Krozingen, Germany).
3. Results
3.1. Bid knockout prevents mitochondrial dysfunction independent of
glutathione depletion in paradigms of ferroptosis and oxytosis
For investigating the eﬀects of erastin in neuronal HT-22 cells and
in particular, the role of BID in this cell death paradigm, we generated
an HT-22 Bid knockout cell line (HT-22 Bid KO) using the CRISPR/
Cas9 technology. Genetic deletion of BID was veriﬁed by Western blot
analysis (Fig. 1a) and indel mutations by CRISPR/Cas9 analyzed by
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Fig. 1. Bid KO does not inhibit glutathione depletion, but prevents ROS formation. a: Western blot veriﬁed knockout of Bid (22 kDa) in HT-22 Bid KO cells. b: Sequencing of the Bid
CRISPR target region revealed diﬀerent indel mutations in the alleles indicated as multiple peaks. c, d: Measurement of glutathione (GSH) depicted rapid decrease of GSH after
glutamate (8 mM; c) or erastin (1 µM; d) exposure which was not restored by Bid KO (n=4/treatment condition). e: BODIPY 581/591 staining and subsequent FACS analysis for
measurement of lipid peroxide formation showed time-dependent increase in the ﬂuorescence after erastin (1 µM) exposure in HT-22 WT cells (n=3/treatment condition). f: MitoSOX
staining and subsequent FACS analysis revealed time-dependent mitochondrial ROS formation after erastin (1 µM) exposure in HT-22 cells (n=3/treatment condition). g: Cells were
stained with BODIPY 581/591 and changes of ﬂuorescence were detected by FACS analysis after 10 h of glutamate (7.5 mM) or erastin (1 µM) treatment. Bid KO fully prevented the
formation of lipid peroxides compared to WT control cells (n=4/treatment condition). h: MitoSOX staining and subsequent FACS analysis depicted reduced formation of mitochondrial
ROS in HT-22 Bid KO cells compared to WT HT-22 cells after erastin (1 µM, 19 h) or glutamate (7 mM, 19 h) challenge (n=4/treatment condition). All data are given as mean + S.D. #p
< 0.05, ###p < 0.001 compared to untreated HT-22 control; ***p < 0.001 compared to erastin-/ glutamate-treated HT-22 control (ANOVA, Scheﬀé‘s test).
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BID is the mediator of mitochondrial dysfunction downstream of
glutathione (GSH) depletion in the model of oxytosis [25].
Consequently, in the present study Bid KO did not prevent gluta-
mate-induced depletion of GSH (Fig. 1c). Like glutamate, erastin
induced a pronounced loss of GSH in a time-dependent manner in
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staining and FACS analysis was used to address the formation of lipid
peroxides after GSH depletion and subsequent activation of 12/15-
lipoxygenases [21,25]. Increasing levels of lipid peroxides were mea-
sured in WT HT-22 cells and MEF cells (Supp. 1a) 6 h after erastin
exposure in a time-dependent manner (Fig. 1e) whereas BID deletion
signiﬁcantly prevented lipid peroxide formation upon glutamate or
erastin treatment (Fig. 1g).
Loss of mitochondrial membrane potential and ROS formation in
mitochondria succeeding lipid peroxidation were investigated by FACS
analysis of TMRE and MitoSOX red ﬂuorescence, respectively. TMRE
ﬂuorescence started to decrease at 6 h (Supp. 2a) and MitoSOX
ﬂuorescence increased at 8 h after erastin exposure in WT HT-22 cells
(Fig. 1f) and in MEF cells (Supp. 1b). At the same time ATP levels
started to decrease at 6–8 h after erastin challenge in WT HT-22 cells
(Supp. 2b) indicating functional loss of mitochondria. Despite the
exposure to glutamate or erastin HT-22 Bid KO cells showed mito-
chondrial ROS formation maintained at the levels of untreated controls
(Fig. 1h).
Furthermore, we observed time-dependent changes of mitochon-
drial morphology in response to erastin toxicity comprising mito-
chondrial fragmentation and accumulation around the nucleus
(Fig. 2a). In order to quantify these morphological changes, we
established a classiﬁcation system [13] consisting of three categories
(for details see materials and methods). Brieﬂy, cells predominantly
showing fragmented mitochondria around the nucleus are assigned to
category III. Cells containing a network of elongated mitochondria
were assigned to category I. The quantiﬁcation of mitochondrial
shape after erastin treatment showed a signiﬁcant increase in cells of
category III in HT-22 WT cells after 8 h (Fig. 2b) matching the
aforementioned increase in mitochondrial ROS formation as an
additional hallmark of mitochondrial damage. Despite glutamate or
erastin challenge, mitochondria in HT-22 Bid KO cells maintained a
network of tubule-shaped morphology being characteristic for
healthy and functional mitochondria (Fig. 2c). The quantiﬁcation of
mitochondrial morphology showed a signiﬁcant increase in cells of
category III after glutamate or erastin treatment in HT-22 WT cells,
while the mitochondrial pattern in HT-22 Bid KO cells remained
similar to control cells (Fig. 2d).
For the purpose of correlating morphology with functionality, we
next examined ATP levels. Both erastin and glutamate induced a
pronounced loss of ATP in HT-22 WT cells, which was fully prevented
in HT-22 Bid KO cells (Fig. 2e). Measurements of the mitochondrial
oxygen consumption rate (OCR), which reﬂects the mitochondrial
respiration conﬁrmed preserved mitochondrial function in HT-22 Bid
KO after treatment with glutamate or erastin. Under basal conditions,
the OCR of Bid KO cells did not diﬀer from WT HT-22 cells (Fig. 2f, g).
In these cells, both glutamate (Fig. 2f) and erastin (Fig. 2g) led to a
strong reduction of the mitochondrial respiration indicated by a hardly
detectable OCR, while HT-22 Bid KO cells showed normal respiration
in the presence of both, glutamate or erastin. These measurements
conﬁrmed the results of the ATP assay and further emphasized
preserved mitochondrial respiration in Bid KO cells. In line, mitochon-
drial membrane potential (MMP), which is essential for neuronal
function and maintenance [18] was restored in both paradigms of
oxidative stress (Fig. 2h). Consistent with previous observations
[13,16], glutamate induced a reduction of the MMP indicated by
reduced TMRE ﬂuorescence, and similar eﬀects were observed after
erastin treatment in the WT HT-22 cells (Fig. 2h). Bid KO protected the
cells against a loss of MMP after exposure of either glutamate or erastin
(Fig. 2h).
Taken together, these ﬁndings demonstrate a pivotal role for BID
mediating mitochondrial dysfunction, formation of mitochondrial ROS
and cell death in the models of glutamate-induced oxytosis and in
erastin-induced ferroptosis suggesting that BID serves as the link
between these distinct paradigms of oxidative death in neuronal cells.
3.2. BID deletion prevents erastin- and glutamate-induced cell death
Erastin-induced ferroptosis gradually leads to cell death quantiﬁed
by FACS analysis of Annexin V and propidium iodide (PI) stained WT
HT-22 cells (Fig. 3a) and MEF cells (Supp. 1c). However, both erastin-
and glutamate-induced cell death measured by Annexin V/PI staining
in WT HT-22 cells was fully inhibited by Bid KO (Fig. 3b).
Furthermore, the BID-inhibitor BI-6c9 prevented death measured by
MTT ﬂuorescence of wild-type (WT) HT-22 cells after both erastin and
glutamate exposure to a similar extent as the HT-22 Bid KO under-
lining the pivotal role of BID in both paradigms of oxidative cell death
(Fig. 3c). In line with our previous studies [19], detailed analysis of cell
viability showed that the protective eﬀect of BI-6c9 against glutamate
and erastin is dose-dependent (Supp. 3a and 3b). Real-time impedance
measurements of cell viability after glutamate (Fig. 3d) and erastin
(Fig. 3e) treatment revealed a sustained protective eﬀect in HT-22 Bid
KO cells compared to HT-22 WT cells. Overexpression of tBID, the
activated form of BID, induced death of both HT-22 WT and HT-22 Bid
KO cells indicated by a reduction of the cell index (Fig. 3f).
In summary these data further emphasize the decisive role of BID
in both model systems validated by oxidative stress resistance owing to
Bid KO.
3.3. BI-6c9 inhibits erastin-induced cell death and subsequent
mitochondrial damage
In order to conﬁrm the protective eﬀects of BID deletion, we evaluated
the neuroprotective potential of the pharmacological BID-inhibitor BI-6c9
against erastin-induced ferroptosis. BI-6c9 prevented erastin-induced cell
death in WT HT-22 cells to a similar extent as the ferroptosis-inhibitor
ferrostatin-1 [7], which was used as a positive control (Fig. 4a). Since
ferroptosis was proposed to result from formation of soluble and lipid
ROS [7] we next examined formation of lipid and mitochondrial ROS. BI-
6c9 fully prevented erastin-induced lipid peroxidation (Fig. 4b) and
further formation of mitochondrial ROS measured via MitoSOX red
staining and subsequent FACS analysis (Fig. 4c).
Comparable to genetic deletion of BID, BI-6c9 was able to inhibit
mitochondrial fragmentation in response to erastin exposure (Fig. 4d).
Furthermore, BI-6c9 preserved mitochondrial function which was
indicated by restoration of the MMP (Fig. 4e) and the ATP levels
(Fig. 4f) after erastin exposure.
Taken together, these results conﬁrm that erastin-induced ferrop-
tosis involves mitochondrial damage [15,30] in neuronal HT-22 cells
and substantiates the pivotal role of BID in ferroptosis which was
observed before in HT-22 Bid KO cells.
Fig. 2. Bid KO preserves mitochondrial integrity. a: Representative images show mitochondrial morphology in HT-22 WT cells in the presence and absence of erastin (1 µM, 2–12 h)
(63x objective). Scale bar: 50 µm. b: Quantiﬁcation of 500 cells counted blind to treatment of conditions of 3 independent experiments revealed time-dependent mitochondrial ﬁssion in
HT-22 cells after erastin (1 µM) exposure. c: Representative images show mitochondrial morphology in HT-22 WT and Bid KO cells in the presence and absence of glutamate (5 mM,
15 h) or erastin (0.5 µM, 15 h) (63x objective). Scale bar: 50 µm. d: Quantiﬁcation of 500 cells counted blind to treatment of conditions of 3 independent experiments revealed reduction
of glutamate/ erastin-induced mitochondrial ﬁssion in Bid KO cells. e: After 17 h of treatment with glutamate (7 mM) or erastin (1 µM) ATP levels were measured. Bid KO prevented
ATP depletion compared to WT controls (n=8/treatment condition). f, g: Measurement of the oxygen consumption rate (OCR) revealed restored basal and maximal respiration in Bid KO
cells compared to WT controls after 16 h glutamate (2 mM; e) or erastin (0.25 µM; f) exposure (n=6/treatment condition). h: HT-22 Bid KO cells exhibited restored MMP measured by
TMRE ﬂuorescence compared to WT HT-22 cells after glutamate (7 mM, 19 h) or erastin (1 µM, 19 h) exposure (n=4/treatment condition). All data are given as mean +S.D. or ± S.D.
##p < 0.01; ###p < 0.001 compared to untreated HT-22 control, ***p < 0.001 compared to erastin-/ glutamate-treated HT-22 control (ANOVA, Scheﬀé‘s test).
S. Neitemeier et al. Redox Biology 12 (2017) 558–570
563
3.4. Ferrostatin-1 prevents glutamate-induced cell death and
preserves mitochondrial integrity
In line with earlier observations [14], the ferroptosis inhibitor
ferrostatin-1 prevented glutamate-induced oxytosis as eﬀective as the
BID-inhibitor BI-6c9 (Fig. 4b) suggesting a shared pathway of both
cell death paradigms, oxytosis and ferroptosis in neuronal HT-22
cells.
To exclude an eﬀect speciﬁc for HT-22 cells, we additionally used
both erastin and glutamate in mouse embryonic ﬁbroblasts (MEFs).
Erastin (Supp. 1d) and glutamate (Supp. 1e) induced cell death in
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tatin-1 were able to prevent death of MEF cells in response to erastin
exposure (Supp. 1f). As negative controls and to conﬁrm the speciﬁcity
of the inhibitors we used the models of H2O2-induced cell death and
necroptosis induced by the combination of TNFα, SM-164 and QVD.
Neither BI-6c9 nor ferrostatin-1 showed a protective eﬀect against
H2O2 (Supp. 4a) or necroptosis (Supp. 4b).
In order to support the conclusion that oxytosis and ferroptosis
share common pathways in neurons, we analyzed the eﬀects of the
ferroptosis inhibitor ferrostatin-1 on lipid peroxidation and mitochon-
drial integrity in the model of oxytosis. Ferrostatin-1 was able to fully
prevent glutamate-induced lipid peroxidation (Fig. 5b), the crucial step
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Fig. 4. BI-6c9 prevents erastin-induced cell death and mitochondrial demise. a: MTT assay revealed protection of BI-6c9 (10 µM) and ferrostatin-1 (2 µM) against erastin (1 µM, 16 h)
toxicity (n=8). b: Cells were stained with BODIPY 581/591 and lipid peroxides were measured by FACS analysis after 16 h of erastin treatment (1 µM). BI-6c9 signiﬁcantly reduced the
lipid peroxide production (n=4/treatment condition). c: Mitochondrial ROS production was detected by MitoSOX staining and following FACS analysis. Erastin increased ROS
production, which was blocked by BI-6c9 (n=4/treatment condition). d: Quantiﬁcation of mitochondrial morphology in cells exposed to erastin (1 µM, 16 h) showed an increase in cells
with mitochondria of category III. This erastin-induced fragmentation was fully prevented by BI-6c9. Mean values were pooled from 4 independent experiments, where mitochondrial
morphology was determined from at least 500 cells per condition without knowledge of treatment history. ##p < 0.01 compared to Cat III of untreated control; *p < 0.05 compared to
Cat III of erastin-treated cells (ANOVA, Scheﬀé’s test). e: Quantiﬁcation of TMRE ﬂuorescence of n=4 independent experiments showed that MMP was fully restored by BI-6c9 (10 µM)
after erastin exposure (1 µM, 16 h). f: After 16 h of treatment with erastin (1 µM) ATP levels were measured. BI-6c9 prevented ATP depletion compared to erastin-treated controls
(n=8). Data are shown as mean + SD. ###p < 0.001 compared to untreated control; ***p < 0.001 compared to erastin-treated control. (ANOVA, Scheﬀé‘s test).
Fig. 3. Bid KO prevents glutamate- and erastin induced cell death. a: Annexin V/PI double staining and subsequent FACS analysis revealed time-dependent cell death after erastin
(1 µM) exposure in HT-22 cells (n=3/treatment condition). b: Representative plots of Annexin V/PI staining and subsequent FACS analysis showed increase in Annexin V (Green
ﬂuorescence) and PI (Red ﬂuorescence) positive cells after glutamate (7 mM, 16 h) and erastin (1 µM, 16 h) exposure in HT-22 WT cells. In Bid KO cells, neither erastin nor glutamate
altered the amount of Annexin V or PI positive cells. Numbers in the dot blots present percentage mean ± S.D. of AV positive cells (lower right) and AV+PI positive cells (upper right)
(n=4) c: MTT conﬁrmed protection of HT-22 Bid KO cells against erastin (1 µM, 16 h) and glutamate (7 mM, 16 h) exposure. Furthermore, in HT-22 WT cells, the BID-inhibitor BI-6c9
(10 µM) fully prevented cell death in response to oxidative stress (n=8/treatment condition). d, e: Real-time impedance measurements revealed protective eﬀect of Bid KO against both
glutamate (7 mM; d) and erastin (1 µM; e) toxicity. Data were derived from the same experiment, but shown in separated graphs for better visualization; (n=6/treatment condition). f:
Over-expression of tBid (0.75 µg plasmid-DNA/well) induced death of both WT and Bid KO HT-22 cells detected by xCELLigence recordings (n=6/treatment condition), representative
experiment shown. All data are given as mean +S.D. or ± S.D. ###p < 0.001 compared to untreated control; ***p < 0.001 compared to erastin-/ glutamate-treated HT-22 control
(ANOVA, Scheﬀé‘s test).
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Moreover, ferrostatin-1 fully blocked glutamate-induced formation
of mitochondrial ROS (Fig. 5c) and further prevented glutamate-
induced mitochondrial fragmentation (Fig. 5d). Aside from that,
ferrostatin-1 (Fig. 5e) restored the MMP and prevented loss of ATP
levels after induction of oxidative stress by glutamate (Fig. 5f). In order
to conﬁrm the protective eﬀects of ferroptosis inhibition in paradigms
of oxytosis, we also applied the recently described ferroptosis inhibitor
liproxstatin-1 [9] in the present model systems of erastin-induced
ferroptosis and glutamate-induced oxytosis in HT-22 cells. In both
paradigms of oxidative death, liproxstatin-1 prevented cell death, and
rescued associated hallmarks of mitochondrial damage in a concentra-
tion-dependent manner and independently of GSH depletion, similar
to the BID-inhibitor BI-6c9, genetic deletion of BID and the ferroptosis
inhibitor ferrostatin-1 (Supp. 5 and 6). Overall, these experiments
using the ferroptosis inhibitors in paradigms of glutamate-induced cell
death suggest shared pathways of oxytosis and ferroptosis in neuronal
cells and MEFs, which include mitochondrial damage mediated by BID.
3.5. BI-6c9 and ferrostatin-1 prevent BID translocation to the
mitochondria
The translocation of the pro-apoptotic protein BID to the mito-
chondria is considered to be crucial for the loss of MMP and the
subsequent decrease of ATP levels [16]. Hence, we investigated the
subcellular distribution of BID in response to erastin and glutamate-
induced stress, respectively. To this end, HT-22 WT cells were co-
transfected with a red-labeled BID and a mitochondrial-targeted GFP
vector as described before [16,19]. Confocal microscopy pictures reveal
a translocation of BID to the mitochondria upon erastin and glutamate
exposure indicated by the merging ﬂuorescence shown in yellow and a
Pearson's coeﬃcient of r=0.78+0.18 and r=0.67+0.06 respectively.
Under control conditions BID was spread all over the cytosol and did
not show any co-localization with the mitochondria (r=0.31+0.05).
This distribution pattern of BID was preserved in cells co-treated with





































































































































































Fig. 5. Ferrostatin-1 inhibits glutamate-induced oxytosis and preserves mitochondrial integrity. a: MTT assay revealed protection of BI-6c9 (10 µM) and ferrostatin-1 (2 µM) against
glutamate (4 mM, 16 h) toxicity (n=8). b: Cells were stained with BODIPY 581/591 and lipid peroxides were measured by FACS analysis after 16 h of glutamate treatment (3 mM).
Ferrostatin-1 signiﬁcantly reduced the lipid peroxide production (n=4). c: Glutamate treatment (3 mM, 16 h) increased mitochondrial ROS production, which was fully blocked by co-
treatment with 2 µM ferrostatin-1 (n=4). d: Quantiﬁcation of mitochondrial morphology in cells exposed to glutamate showed an increase in cells with mitochondria of category III. This
glutamate-induced fragmentation was fully prevented by ferrostatin-1. ##p < 0.01 compared to Cat I of glutamate-treated control; ***p < 0.001 compared to Cat III of glutamate-treated
cells (ANOVA, Scheﬀé’s test). Mean values were pooled from 4 independent experiments, where mitochondrial morphology was determined from at least 500 cells per condition without
knowledge of treatment history. e: Quantiﬁcation of TMRE ﬂuorescence of n=4 independent experiments showed that MMP was fully restored by ferrostatin-1 (2 µM) after glutamate
exposure (3 mM, 16 h). f: After 16 h of treatment with glutamate (3 mM) ATP levels were measured. Ferrostatin-1 prevented ATP depletion compared to glutamate-treated controls
(n=8). All results are given as mean + S.D. ###p < 0.001 compared to untreated control; ***p < 0.001 compared to glutamate-treated control (ANOVA, Scheﬀé‘s test).
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cells treated with ferrostatin-1 and glutamate (r=0.18+0.04), respec-
tively (Fig. 6a, Supp. 7). These results indicate that the diﬀerent
substances, the BID-inhibitor BI-6c9 and the ferroptosis inhibitor
ferrostatin-1 prevent the translocation of BID to the mitochondria.
3.6. The BID-inhibitor BI-6c9 but not ferrostatin-1 aﬀects tBID-
induced cell death
In order to shed more light on the direct eﬀects of both inhibitors,
BI-6c9 and ferrostatin-1, we applied a model of tBID-overexpression in
the HT-22 WT cell line. Following previously established protocols
[19,25], we transfected HT-22 cells with a tBID-encoding plasmid and
analyzed cell viability 24 h after the transfection. Annexin V/PI staining
revealed that BI-6c9 signiﬁcantly reduced tBID-induced cytotoxicity
similar to earlier ﬁndings [19], while ferrostatin-1 failed to protect HT-
22 cells from tBID toxicity (Fig. 6b, c).
These results indicate that mitochondrial transactivation of BID is
the key decision point of cell death connecting the mechanisms of
ferroptosis and oxytosis in neuronal cells. Once activated, the detri-
mental activity of BID cannot be stopped by inhibitors of ferroptosis
such as ferrostatin-1 that act upstream of the fatal BID transactivation
and associated mitochondrial demise.
Assuming oxytosis and ferroptosis to share common mechanistic
hallmarks, apoptosis inducing factor (AIF) translocation, which is essen-
tial for cell death in oxytosis, was expected to be required for ferroptosis as
well. Therefore we depleted WT HT-22 cells of AIF by siRNA and
analyzed cell viability upon glutamate or erastin challenge by real-time
impedance measurements. We found AIF depleted cells to be protected
against cell death compared to control siRNA conditions (Supp. 8).
4. Discussion
The present study exposes BID as a key link of death signaling
pathways of ferroptosis and oxytosis to mitochondrial damage in
neuronal cells. Erastin induced morphological and functional damage
of mitochondria such as enhanced fragmentation, increased formation
of mitochondrial ROS, loss of MMP and ATP depletion in a very similar
pattern as the hallmarks of oxytosis triggered by glutamate in the
neuronal HT-22 cells [12,13,16,19,25]. Further, using CRISPR/Cas9
technology for genetic BID deletion and the pharmacological BID-
inhibitor BI-6c9 we identiﬁed a key role for BID in mediating the
hallmarks of erastin toxicity. Vice versa, the ferroptosis inhibitor
ferrostatin-1 blocked BID transactivation, mitochondrial fragmenta-
tion and the loss of MMP after glutamate exposure in neuronal cells,
conﬁrming that oxytosis and ferroptosis share detrimental mechanisms
of ROS formation upstream of BID-dependent mitochondrial demise.
It has been established that both forms of death pathways, oxytosis
and ferroptosis induced by glutamate and erastin, respectively, involve
very similar mechanisms, i.e. inhibition of the Xc
- system, GSH
depletion and subsequent lipid peroxidation [8]. In both model systems
Gpx4 is considered as an important negative regulator of lipid
peroxidation [21,29]. In contrast to glutamate, which in neuronal
HT-22 cells acts as a competitive inhibitor of cystine import through
Xc
-, erastin was supposed to mediate direct detrimental eﬀects at the
Fig. 6. Bid links ferroptosis to mitochondrial cell death. a: Confocal microscopy pictures revealed translocation of BID (Bid-dsRed) to the mitochondria (MitoGFP) after erastin (1 µM,
16 h) or glutamate (3 mM, 16 h) exposure, which was fully blocked by BI-6c9 or ferrostatin-1 co-treatment. Scale bar: 20 µM. b: tBID-induced cell death (2 µg plasmid/24-well, 24 h) in
HT-22 cells was analyzed by co-staining of cells with Annexin V (Green ﬂuorescence) and PI (Red ﬂuorescence) and subsequent FACS-analysis. Pre-incubation for 1 h with 10 µM BI-6c9
prevented pIRES-tBid-induced cell death, while ferrostatin-1 did not (representative dot plots). The empty vector pcDNA3.1 was used as a control plasmid. Numbers in the
representative dot blots show percentage of AV positive cells (lower right) and AV+PI positive cells (upper right) (n=4) c: Quantiﬁcation of dot plots shown in b (n=4). Data are shown as
mean + S.D. ###p < 0.001compared to cDNA 3.1; ***p < 0.001compared to pIRES-tBid-transfected control (ANOVA, Scheﬀé‘s test).
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mitochondria [15,30,7]. For example, erastin altered the permeability
of the outer mitochondrial membrane via interaction with particular
isoforms of the voltage-dependent anion channel (VDAC) thereby
inducing mitochondria-triggered oxidative cell death in tumor cells
[28]. Notably, Dixon and coworkers observed erastin-induced altera-
tions of mitochondrial morphology, but could not detect any formation
of mitochondrial ROS in their experimental settings [7], whereas Yuan
et al. observed the induction of mitochondrial ROS by erastin [30].
In contrast, the present study clearly indicates that mitochondrial
damage is a prerequisite for cell death pathways of ferroptosis in
neuronal cells. In particular, the observed translocation of ﬂuorescently
labeled BID in erastin-exposed cells suggested a major role for this pro-
apoptotic protein in ferroptosis. This conclusion was further conﬁrmed
by protective eﬀects of the BID-inhibitor BI-6c9 and Bid knockout in
the model system of ferroptosis in neural cells, which contrasts
previous observations in cancer cells where BID was not required for
erastin-induced toxicity [7]. Downstream events of BID transactivation
such as mitochondrial ROS formation, drop of MMP and ATP were
detected here, thereby conﬁrming erastin-induced mitochondrial de-
mise in neuronal cells.
Our ﬁndings are in line with earlier studies exposing a pivotal role for
BID transactivation to mitochondria in neuronal cell death, in models of
glutamate excitotoxicity and oxygen glucose-deprivation, and, further-
more, in vivo, in models of cerebral ischemia and brain trauma
[1,12,13,16,2,20,5]. In particular, our previous work demonstrated that
BID mediated mitochondrial fragmentation in neurons through en-
hanced mitochondrial recruitment of dynamin-related protein 1 (Drp-
1), a GTPase that mediates mitochondrial ﬁssion [12]. Further, BID was
shown to mediate enhanced mitochondrial ROS production and loss of
mitochondrial membrane integrity as demonstrated by measurements of
MMP and mitochondrial release of apoptosis-inducing factor in the
model of glutamate-induced oxytosis [16,25].
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Fig. 7. Bid links ferroptosis to neuronal oxytosis. Glutamate and erastin inhibit the Xc
--antiporter in paradigms of oxytosis and ferroptosis, respectively. Blocking the cellular cystine
import results in decreased GSH levels and reduced Gpx4 activity, and the subsequent activation of 12/15 LOX mediates signiﬁcant formation of reactive oxygen species (ROS). In
erastin-induced ferroptosis cell death is induced through oxidative stress and independently of mitochondrial demise. In neuronal cells, ROS-induced transactivation of BID to the
mitochondria links both pathways of oxytosis and ferroptosis, and causes mitochondrial ROS formation that is associated with irreversible morphological and functional damage, e.g.
loss of MMP, decline of ATP levels and release of apoptosis inducing factor (AIF). The BID-inhibitor BI-6c9 and the ferroptosis inhibitors ferrostatin-1 and liproxstatin-1 are able to
block these fatal pathways upstream of mitochondrial impairments. BI-6c9 directly inhibits BID and its detrimental eﬀects at the level of mitochondria while ferrostatin-1 acts upstream
of BID preventing ROS formation through 12/15 LOX.
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The current study suggests that the concept of BID-mediated
mitochondrial damage in oxytosis can be also transferred to mechan-
isms of ferroptosis in neuronal cells. In fact, inhibition of BID blocked
the detrimental eﬀects of erastin at the level of mitochondria. Notably,
ferrostatin-1 failed to prevent tBID-induced cell death, suggesting that
BID serves as a sensor for iron-dependent generation of oxidative
stress and BID transactivation to mitochondria as the “point of no
return” determines neuronal death [10]. Our data strongly suggest that
oxytosis and ferroptosis share common mechanisms upstream of BID
transactivation and mitochondrial damage, since ferrostatin-1 and
liproxstatin-1 were able to prevent formation of ROS, transactivation
of BID and the associated mitochondrial damage, and neuronal death
in the model of glutamate-induced oxytosis.
In conclusion, our data suggest that ferroptosis in neurons is
merged with pathways of oxytosis through BID transactivation to
mitochondria (Figs. 6 and 7). Diﬀerent signaling pathways and
additional control points of cell death are expected in neurons in
comparison to other cell types, in particular in comparison to highly
proliferating cancer cells because neurons are highly diﬀerentiated and
specialized cells which have to maintain function and viability through-
out the lifespan of the organism, which means e.g. for more than 80
years in humans. During such a lifespan highly diﬀerentiated neurons
are exposed to a number of stress insults, including oxidative stress,
which has been associated as a leading mechanism in ageing and age-
related neurodegenerative diseases [3,4]. Our present ﬁndings support
the view that BID-mediated mitochondrial damage is a prerequisite for
death signaling in neurons in paradigms of severe oxidative stress.
Such BID-dependent mitochondrial death pathways involve fragmen-
tation of the organelles, impaired ATP synthesis, and loss of MMP and
mitochondrial membrane integrity resulting in the release of pro-
apoptotic factors such as cytochrome c, endonuclease G and AIF [10].
Overall, the present study exposes BID as the molecular link
between the previously separated pathways of oxidative stress signaling
by merging the death pathways of ferroptosis and oxytosis at the level
of mitochondria, i.e. the crucial point of decision for neuronal function
and survival. This concept of merged death pathways of oxytosis and
ferroptosis in neurons may provide new therapeutic approaches as
intervention strategies may prove successful in preventing neuronal
death at diﬀerent levels of cellular stress. Such approaches may include
ferroptosis inhibitors, inhibitors of lipid peroxidation, and, in parti-
cular, strategies of mitochondrial protection through inhibition of BID.
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